1063 related articles for article (PubMed ID: 15503021)
21. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
[TBL] [Abstract][Full Text] [Related]
22. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
23. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
[TBL] [Abstract][Full Text] [Related]
24. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Savini A; Alesiani F; Brunori M; Catarini M; Visani G; Samori A; Burattini M; Centurioni R; Montanari M; Fraticelli P; Ruggieri M; Falcioni S; Galieni P
Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733
[TBL] [Abstract][Full Text] [Related]
25. Symptom burden after autologous stem cell transplantation for multiple myeloma.
Campagnaro E; Saliba R; Giralt S; Roden L; Mendoza F; Aleman A; Cleeland C; Weber D; Brown J; Anderson KO
Cancer; 2008 Apr; 112(7):1617-24. PubMed ID: 18260091
[TBL] [Abstract][Full Text] [Related]
26. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
27. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
28. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
30. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
31. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
33. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
34. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
36. [The impact of autologous stem cell transplantation on the prognosis in multiple myeloma].
Li YH; Hou J; Wang DX; Fu WJ; Yuan ZG; Chen YB; Xi H
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):222-5. PubMed ID: 18843973
[TBL] [Abstract][Full Text] [Related]
37. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
[TBL] [Abstract][Full Text] [Related]
38. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
40. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
